Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure

Area of Science:

• Cardiovascular Biology
• Genomics
• Molecular Medicine

Background:

• Heart failure from dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) share clinical outcomes but differ in underlying molecular and remodeling pathways.
• Microarray technology has become instrumental in advancing the understanding of complex diseases like heart failure.

Purpose of the Study:

• To construct and validate an in-house cDNA microarray for analyzing gene expression in heart failure.
• To identify differentially expressed genes in left ventricular tissues of DCM and HCM patients compared to normal hearts.

Main Methods:

• Development of a custom spotted cDNA microarray with 10,272 unique clones.
• Hybridization of RNA from DCM and HCM patient left ventricles against normal adult heart reference RNA.
• Application of novel analysis software to identify differentially expressed genes, with validation by quantitative real-time reverse transcription-PCR.

Main Results:

• Demonstrated slide-dependent and nonlinear normalization for cDNA microarray data.
• Identified 192 genes upregulated and 51 genes downregulated in both DCM and HCM.
• Discovered distinct gene expression profiles differentiating DCM from HCM, including genes like alphaB-crystallin and calsequestrin.

Conclusions:

• Microarray technology provides a powerful genomic approach to uncover genetic markers and molecular mechanisms driving heart failure in DCM and HCM.
• The study highlights both common and distinct molecular pathways in DCM and HCM, paving the way for targeted therapeutic strategies.